Advances in therapeutic options, including endocrine therapies, bisphosphonates, ovarian function suppression, olaparib, and CDK4/6 inhibitors, have markedly improved patient outcomes.However,these advancements also introduce complexities in implementation,monitoring,and resource allocation. Notably,therapies such as CDK4/6 inhibitors demand particularly close monitoring,placing logistical and capacity strain on medical oncologists already managing increasing cancer incidence and treatment complexities.

To address these challenges, innovative care delivery solutions are essential to ensure patients with EBC continue to receive optimal care. This paper presents a comprehensive guide-a playbook-of multidisciplinary, team-based care models designed to optimize adjuvant treatment delivery in EBC. Drawing on real-world evidence and accomplished applications across Canadian centers, the paper explores models led by nurses, nurse practitioners (NPs), general practitioners in oncology (GPO), and pharmacists.

each model leverages the unique expertise of its team to manage treatment toxicities, facilitate adherence, and enhance patient education, thereby promoting effective and lasting care delivery. these models are intended to be flexible, serving as a resource from which breast cancer care teams can draw strategies tailored to their local resources and patient needs, rather than competing with one another.

By detailing implementation strategies, benefits, and challenges-often supported by quantitative metrics and economic evaluations-this work aims to inspire care teams nationwide to optimize the adjuvant management of patients with HR+, HER2- EBC.

evergreen Insights

Background: Hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) early breast cancer (EBC) is the most common subtype of breast cancer. Adjuvant therapy aims to reduce the risk of recurrence and improve survival after primary treatment.

Context: The introduction of novel agents like CDK4/6 inhibitors has expanded treatment options but also increased the complexity of care delivery. Ensuring equitable access to these therapies and managing their associated toxicities requires efficient and coordinated care models.

past Trends: Historically, adjuvant breast cancer care has been primarily managed by medical oncologists. However, the increasing complexity and volume of cancer care have led to the exploration and implementation of team-based approaches, leveraging the skills of various healthcare professionals to optimize patient management and resource utilization.

Frequently Asked Questions

What are the main challenges in adjuvant treatment for HR+, HER2- EBC?

Key challenges include the complexity of implementing and monitoring new therapies like CDK4/6 inhibitors, managing treatment toxicities, ensuring patient adherence, and addressing the logistical and capacity demands on medical oncologists.

What types of multidisciplinary care models are discussed?

The paper explores models led by nurses, nurse practitioners (NPs), general practitioners in oncology (GPO), and pharmacists, each leveraging specific expertise to enhance patient care.

What is the goal of these care models?

The goal is to optimize adjuvant treatment delivery by improving toxicity management, facilitating adherence, enhancing patient education, and promoting sustainable, patient-centered care within existing healthcare resources.

This article provides general facts on cancer treatment strategies and does not constitute medical, financial, or legal advice. Consult with qualified healthcare professionals for personalized guidance.